F
Franck E. Nicolini
Researcher at French Institute of Health and Medical Research
Publications - 302
Citations - 12215
Franck E. Nicolini is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 45, co-authored 275 publications receiving 10374 citations. Previous affiliations of Franck E. Nicolini include University of British Columbia.
Papers
More filters
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian,Francis J. Giles,Norbert Gattermann,Kapil N. Bhalla,Giuliana Alimena,Francesca Palandri,Gert J. Ossenkoppele,Franck E. Nicolini,Stephen G. O'Brien,Mark R. Litzow,Ravi Bhatia,Francisco Cervantes,Ariful Haque,Yaping Shou,Debra Resta,Aaron Weitzman,Andreas Hochhaus,Philipp le Coutre +17 more
TL;DR: Nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance and was effective in patients harboring BCR-ABL mutations associated with imatinIB resistance (except T315I), and also in Patients with a resistance mechanism independent of B CR-ABl mutations.
Journal ArticleDOI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more
TL;DR: An expert panel to critically evaluate and update the evidence to achieve goals to achieve a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR) in chronic myeloid leukemia.
Journal ArticleDOI
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian,Neil P. Shah,Jorge E. Cortes,Michele Baccarani,Mohan B. Agarwal,Maria Soledad Undurraga,Jianxiang Wang,Juan Julio Kassack Ipiña,Dong-Wook Kim,Michinori Ogura,Carolina Pavlovsky,Christian Junghanss,Jorge Milone,Franck E. Nicolini,Tadeusz Robak,Jan Van Droogenbroeck,Edo Vellenga,M. Brigid Bradley-Garelik,Chao Zhu,Andreas Hochhaus +19 more
TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
Journal ArticleDOI
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
François Guilhot,Claude Chastang,Mauricette Michallet,A. Guerci,Jean Luc Harousseau,Frédéric Maloisel,R. Bouabdallah,Denis Guyotat,Cheron N,Franck E. Nicolini,JF Abgrall,Tanzer J +11 more
TL;DR: The combination of interferon and cytarabine, as compared withinterferon alone, increases the rate of major cytogenetic response and prolongs survival in patients with the chronic phase of chronic myelogenous leukemia.